{"id": "ejg25b", "title": "Just a little coffee for you this morning", "selftext": "*3rd January 2020*\n\nFollowing the US\u2019 attack on several top Iranian officials in Iraq, energy prices have spiked higher, supporting **energy stocks (CVX, XOM, SLB, XOP, XLE)** and defence stocks such as **Lockheed Martin (LMT)** whilst weighing on **airlines (LUV, DAL, AAL)** in addition to dampening appetite for risk in general, **banks (XLF, BKX, JPM, WFC, C, BAC)** particularly will face pressure from the Treasury curve\u2019s bull flattening. With Iran vowing a swift response, participants are cautious of further geopolitical escalation which could see these asset price movements continue, although desks are also cognizant of previous flares of conflict which have proved short-lived in regard to market reactions, such as the swift reversal of oil prices following the attacks of Saudi\u2019s Abqaiq oil facility in September 2019.\n\n#DOW\n\n**Apple Inc. (AAPL)** has had its PT raised to USD 330 both at BofA (prev. USD 290) and RBC (prev. USD 295). BofA analyst Wamsi Mohan cites third-party data as indicating strong double-digit YY growth in App Store revenue, in addition to other positive revenue trends. RBC analyst Robert Muller sees an improved near-term outlook and expectations of a multi-year upgrade cycle to accommodate incoming 5G.\n\n#NASDAQ 100\n\n**Illumina Inc (ILMN)** has mutually agreed with **Pacific Biosciences of California Inc (PACB)** to terminate their merger agreement from 2018, where Illumina was to acquire the latter for USD 1.2bln in cash. UBS analyst Dan Brennan says the announcement is unsurprising following UK and US regulators blocked the deal and the announcement doesn\u2019t change his Buy thesis on Illumina.\n\n**Incyte (INCY)** Phase 3 GRAVITAS-301 study of graft-versus-host disease treatment, itacitinib in combination with corticosteroids, did not meet its primary and secondary endpoints; a slew of research analysts have cut their PTs on the stock as of such, including a downgrade at Mizuho.\n\n**Tesla Inc (TSLA)** has cut its prices for its China-made Model 3s by 16% to USD 42,919, ahead of their delivery, after receiving Chinese subsidies. Elsewhere, Q4 2019 vehicle production achieved record rate of almost 105k, delivering a record 112k (exp. 104k); in 2019 as a whole, TSLA delivered 367.5k units. Model 3 deliveries came in at 92,550 units in Q4 (exp. 86,280); produced 86,958 units of Model 3 in Q4.\n\n#S&amp;P 500\n\n**Humana Inc. (HUM)** has been upgraded to \u2018Conviction Buy\u2019 from \u2018Buy\u2019 at Goldman Sachs with a PT of USD 425, where analyst Stephen Tanel expects significant upward earnings revisions from 2021 and beyond after the recent repeal of the health insurer industry fee.\n\n**Lamb Weston Holdings Inc (LW)** Q2 20 (USD): Adj. EPS 0.80 (exp. 0.84), Revenue 1.02bln (exp. 0.96bln). Raises FY adj. EBITDA view to 965mln-985mln (prev. 950mln-970mln); FY Revenue view in high end of mid-single digit range.\n\n**Newmont Goldcorp (NEM)** following the completion of the divestiture of its 50% stake in Kalgoorlie Consolidated Gold Mines to Northern Star Resources Limited, has lowered its FY20 gold production view to 6.4mln ounces from 6.7mln ounces.\n\n#OTHER\n\n\n**Avon Products Inc (AVP)** \u2013 Natura expects its acquisition of Avon to close and on completion, the delisting of AVP shares and then the listing of Natura ADRs. Current Avon CEO Jan Zijderveld is also to depart the Co on completion of the merger.\n\n**Mattel Inc (MAT)** is to reduce the number of products it sells by 30%, WSJ reports, where it will axe items mainly from the 45% of its offerings that attribute to only 6% of its revenue.\n\n**Sony Corporation (SNE)** has made efforts to penetrate the autonomous vehicle tech market, where it is reportedly working on a silicon-based vision sensor.\n\n**Taiwan Semiconductor Manufacturing (TSM)** could see revenue growth of at least 15% in 2020 driven by strong 7nm chip sales. industry sources also report that TSMC has received orders from **Intel (INTC)** for automotive AI chips, which are expected to attribute to revenue in H2 2020.\n\n**Wesco International Inc (WCC)** has raised its acquisition offer for **Anixter International Inc (AXE)** to USD 97 per share in a cash and stock deal, following private equity firm Clayton Dubilier &amp; Rice offering USD 93.50 per share on Thursday.", "created_utc": 1578061526, "permalink": "/r/wallstreetbets/comments/ejg25b/just_a_little_coffee_for_you_this_morning/", "is_self": true}